ReplyYes, a fast-growing, chat-based commerce startup, announced three additions to the company’s executive board this week: former Zulily engineer Trevor Inman,… Read More
Seattle-based cancer immunotherapy company Juno Therapeutics handily beat analyst expectations for the fourth quarter, posting $21.2 million in revenue, compared to… Read More
New data from Seattle’s Juno Therapeutics shows promising results for one of its immunotherapy treatments, JCAR017. The drug was studied as a treatment… Read More
Juno Therapeutics, the Seattle-based biotech company developing immunotherapy treatments for cancer, announced it has placed a voluntary hold on the clinical… Read More
What does it take for a region to become truly revolutionary? Dr. Richard Klausner, co-founder and director of biotechnology company Juno Therapeutics,… Read More
Juno Therapeutics, a Seattle-based clinical cancer research firm valued at $3.8 billion, has been sued in a class-action lawsuit alleging that the… Read More
Seattle-based Juno Therapeutics has acquired RedoxTherapies for $10 million, to secure exclusive rights to a molecule that may provide a new… Read More
Nohla Therapeutics just became the latest biotech startup to come out of the Fred Hutchinson Cancer Research Center. Like spinouts before it, Nohla is already… Read More
—Lighter Capital appointed Rebecca Conner as a director of its investment team. The Techstars mentor will work with companies in the Pacific Northwest,… Read More
Juno Therapeutics, a Seattle-based cancer research firm backed by Amazon founder Jeff Bezos, Arch Venture Partners and others, reported a loss… Read More
Shares of Seattle-based biotech startup Juno Therapeutics spiked more than 60 percent in after-hours trading on Monday after the company announced… Read More
Seattle-based cancer research startup Juno Therapeutics today reached a settlement with Novartis Pharmaceuticals Corp. over a three-year patent dispute. The original… Read More
Seattle-based cancer research startup Juno Therapeutics today fell short of analyst estimates in its first earnings report. Juno posted a non-GAAP net… Read More
Fast-moving Juno Therapeutics is moving closer to becoming a publicly-traded company. The Seattle biotechnology company today updated is IPO filing… Read More
